On January 14, 2022, Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, announced a $150 million Series E funding round led by Johnson & Johnson Innovation and Novo Growth, the growth-stage investment arm of Novo Holdings. Existing Verana Health investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers also joined the round, as well as notable new investors, including the Merck Global Health Innovation Fund, THVC, and Breyer Capital. Verana Health plans to use the proceeds of the investment to advance its life sciences product and service strategy across the drug lifecycle, further enhance its value proposition to healthcare providers participating in its real-world data network, and expand its data footprint through medical society and strategic partnerships.

Wilson Sonsini advised Verana Health on the transaction. The team included:

Corporate
Megan Baier
Catherine Riley Tzipori
Rui Ke
Annie Schroyer

Employee Benefits and Compensation
Sriram Krishnamurthy
Matthew Norgard

For more information, please see Verana Health’s press release.